Skip to main content
Erschienen in: Quality of Life Research 4/2016

11.09.2015

A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms

verfasst von: Nana Brochmann, Ann-Dorthe Zwisler, Mette Kjerholt, Esben Meulengracht Flachs, Hans Carl Hasselbalch, Christen Lykkegaard Andersen

Erschienen in: Quality of Life Research | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

An Internet-based tool for reporting and analysing patient-reported outcomes (PROs) has been developed. The tool enables merging PROs with blood test results and allows for computation of treatment responses. Data may be visualized by graphical analysis and may be exported for downstream statistical processing. The aim of this study was to investigate, whether patients with myeloproliferative neoplasms (MPNs) were willing and able to use the tool and fill out questionnaires regularly.

Methods

Participants were recruited from the outpatient clinic at the Department of Haematology, Roskilde University Hospital, Denmark. Validated questionnaires that were used were European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, Myeloproliferative Neoplasm Symptom Assessment Form, Brief Fatigue Inventory and Short Form 36 Health Survey. Questionnaires were filled out ≥6 months online or on paper according to participant preference. Regularity of questionnaire submission was investigated, and participant acceptance was evaluated by focus-group interviews.

Results

Of 135 invited patients, 118 (87 %) accepted participation. One hundred and seven participants (91 %) preferred to use the Internet-based tool. Of the 118 enrolled participants, 104 (88 %) submitted PROs regularly ≥6 months. The focus-group interviews revealed that the Internet-based tool was well accepted.

Conclusion

The Internet-based approach and regular collection of PROs are well accepted with a high participation rate, persistency and adherence in a population of MPN patients. The plasticity of the platform allows for adaptation to patients with other medical conditions.
Literatur
1.
Zurück zum Zitat Snyder, C. F., Wu, A. W., Miller, R. S., Jensen, R. E., Bantug, E. T., & Wolff, A. C. (2011). The Role of Informatics in Promoting Patient-Centered Care. Cancer Journal, 17(4), 211–218.CrossRef Snyder, C. F., Wu, A. W., Miller, R. S., Jensen, R. E., Bantug, E. T., & Wolff, A. C. (2011). The Role of Informatics in Promoting Patient-Centered Care. Cancer Journal, 17(4), 211–218.CrossRef
2.
Zurück zum Zitat Novik, A., Salek, S., & Ionova, T. (2012). Patient-reported outcomes in patients with hematological disorders: Conceptual issues. In A. Novik, S. Salek, & T. Ionova (Eds.), Guidelines patient-reported outcomes in hematology (pp. 19–22). Genoa: Forum service editore. Novik, A., Salek, S., & Ionova, T. (2012). Patient-reported outcomes in patients with hematological disorders: Conceptual issues. In A. Novik, S. Salek, & T. Ionova (Eds.), Guidelines patient-reported outcomes in hematology (pp. 19–22). Genoa: Forum service editore.
3.
Zurück zum Zitat Coates, A., Porzsolt, F., & Osoba, D. (1997). Quality of life in oncology practice: Prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. European Journal of Cancer, 33(7), 1025–1030.CrossRefPubMed Coates, A., Porzsolt, F., & Osoba, D. (1997). Quality of life in oncology practice: Prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. European Journal of Cancer, 33(7), 1025–1030.CrossRefPubMed
4.
Zurück zum Zitat Coates, A., Thomson, D., McLeod, G. R., Hersey, P., Gill, P. G., Olver, I. N., et al. (1993). Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. European Journal of Cancer, 29A(12), 1731–1734.CrossRefPubMed Coates, A., Thomson, D., McLeod, G. R., Hersey, P., Gill, P. G., Olver, I. N., et al. (1993). Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. European Journal of Cancer, 29A(12), 1731–1734.CrossRefPubMed
5.
Zurück zum Zitat Skov, V., Thomassen, M., Riley, C. H., Jensen, M. K., Bjerrum, O. W., Kruse, T. A., et al. (2012). Gene expression profiling with the principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Experimental Hematology, 40(9), 771–780.CrossRefPubMed Skov, V., Thomassen, M., Riley, C. H., Jensen, M. K., Bjerrum, O. W., Kruse, T. A., et al. (2012). Gene expression profiling with the principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Experimental Hematology, 40(9), 771–780.CrossRefPubMed
6.
Zurück zum Zitat Scherber, R. M., Geyer, H. L., & Mesa, R. A. (2014). Quality of life in MPN comes of age as a therapeutic target. Current Hematologic Malignancy Reports, 9(4), 324–330.CrossRefPubMed Scherber, R. M., Geyer, H. L., & Mesa, R. A. (2014). Quality of life in MPN comes of age as a therapeutic target. Current Hematologic Malignancy Reports, 9(4), 324–330.CrossRefPubMed
7.
Zurück zum Zitat Geyer, H. L., Emanuel, R. M., Dueck, A. C., Kiladjian, J. J., Xiao, Z., Slot, S., et al. (2014). Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: Retrospective assessment in 1470 patients. Blood, 123(24), 3803–3810.CrossRefPubMedPubMedCentral Geyer, H. L., Emanuel, R. M., Dueck, A. C., Kiladjian, J. J., Xiao, Z., Slot, S., et al. (2014). Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: Retrospective assessment in 1470 patients. Blood, 123(24), 3803–3810.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Mesa, R. A., Niblack, J., Wadleigh, M., Verstovsek, S., Camoriano, J., Barnes, S., et al. (2007). The Burden of Fatigue and Quality of Life in Myeloproliferative Disorders (MPDs): An International Internet-based Survey of 1179 MPD Patients. Cancer, 109(1), 68–76.CrossRefPubMed Mesa, R. A., Niblack, J., Wadleigh, M., Verstovsek, S., Camoriano, J., Barnes, S., et al. (2007). The Burden of Fatigue and Quality of Life in Myeloproliferative Disorders (MPDs): An International Internet-based Survey of 1179 MPD Patients. Cancer, 109(1), 68–76.CrossRefPubMed
9.
Zurück zum Zitat Emanuel, R. M., Dueck, A. C., Geyer, H. L., Kiladjian, J. J., Slot, S., Zweegman, S., et al. (2012). Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. Journal of Clinical Oncology, 30(33), 4098–4103.CrossRefPubMed Emanuel, R. M., Dueck, A. C., Geyer, H. L., Kiladjian, J. J., Slot, S., Zweegman, S., et al. (2012). Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. Journal of Clinical Oncology, 30(33), 4098–4103.CrossRefPubMed
10.
Zurück zum Zitat Cella, D., Nowinski, C. J., & Frankfurt, O. (2014). The impact of symptom burden on patient quality of life in chronic myeloid leukemia. Oncology, 87(3), 133–147.CrossRefPubMed Cella, D., Nowinski, C. J., & Frankfurt, O. (2014). The impact of symptom burden on patient quality of life in chronic myeloid leukemia. Oncology, 87(3), 133–147.CrossRefPubMed
11.
Zurück zum Zitat McMahon, B., & Stein, B. L. (2013). Thrombotic and bleeding complications in classical myeloproliferative neoplasms. Seminars in Thrombosis and Hemostasis, 39(1), 101–111.PubMed McMahon, B., & Stein, B. L. (2013). Thrombotic and bleeding complications in classical myeloproliferative neoplasms. Seminars in Thrombosis and Hemostasis, 39(1), 101–111.PubMed
12.
Zurück zum Zitat Hasselbalch, H. C. (2014). Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Expert Review of Hematology, 7(2), 203–216.CrossRefPubMed Hasselbalch, H. C. (2014). Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Expert Review of Hematology, 7(2), 203–216.CrossRefPubMed
13.
Zurück zum Zitat Abelsson, J., Andréasson, B., Samuelsson, J., Hultcrantz, M., Ejerblad, E., Johansson, B., et al. (2013). Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leukaemia & Lymphoma, 54(10), 2226–2230.CrossRef Abelsson, J., Andréasson, B., Samuelsson, J., Hultcrantz, M., Ejerblad, E., Johansson, B., et al. (2013). Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leukaemia & Lymphoma, 54(10), 2226–2230.CrossRef
14.
Zurück zum Zitat Trask, P., Cella, D., Powell, C., Reisman, A., Whiteley, J., & Kelly, V. (2013). Health-related quality of life in chronic myeloid leukemia. Leukemia Research, 37(1), 9–13.CrossRefPubMed Trask, P., Cella, D., Powell, C., Reisman, A., Whiteley, J., & Kelly, V. (2013). Health-related quality of life in chronic myeloid leukemia. Leukemia Research, 37(1), 9–13.CrossRefPubMed
15.
Zurück zum Zitat Johansson, P., Mesa, R. A., Scherber, R., Abelsson, J., Samuelsson, J., Birgegaard, G., et al. (2012). Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Leukaemia & Lymphoma, 53(3), 441–444.CrossRef Johansson, P., Mesa, R. A., Scherber, R., Abelsson, J., Samuelsson, J., Birgegaard, G., et al. (2012). Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Leukaemia & Lymphoma, 53(3), 441–444.CrossRef
17.
Zurück zum Zitat Scherber, R., Dueck, A. C., Johansson, P., Barbui, T., Barosi, G., Vannucchi, A. M., et al. (2011). The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients. Blood, 118(2), 401–408.CrossRefPubMed Scherber, R., Dueck, A. C., Johansson, P., Barbui, T., Barosi, G., Vannucchi, A. M., et al. (2011). The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients. Blood, 118(2), 401–408.CrossRefPubMed
20.
Zurück zum Zitat Barbui, T., Barosi, G., Birgegaard, G., Cervantes, F., Finazzi, G., Griesshammer, M., et al. (2011). Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of Clinical Oncology, 29(6), 761–770.CrossRefPubMed Barbui, T., Barosi, G., Birgegaard, G., Cervantes, F., Finazzi, G., Griesshammer, M., et al. (2011). Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Journal of Clinical Oncology, 29(6), 761–770.CrossRefPubMed
21.
Zurück zum Zitat Jabbour, E., & Kantarjian, H. (2012). Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. American Journal of Hematology, 87(11), 1037–1045.CrossRefPubMed Jabbour, E., & Kantarjian, H. (2012). Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management. American Journal of Hematology, 87(11), 1037–1045.CrossRefPubMed
22.
Zurück zum Zitat Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases, 40(5), 373–383.CrossRefPubMed Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases, 40(5), 373–383.CrossRefPubMed
23.
Zurück zum Zitat Satu, E., & Kyngäs, H. (2008). The qualitative content analysis process. Journal of Advanced Nursing, 62(1), 107–115.CrossRef Satu, E., & Kyngäs, H. (2008). The qualitative content analysis process. Journal of Advanced Nursing, 62(1), 107–115.CrossRef
24.
Zurück zum Zitat Catanzaro, M. (1988). Using qualitative analytical techniques. In N. F. Woods & M. Catanzaro (Eds.), Nursing research: Theory and practice. C.V. Mosby: St Louis, MO. Catanzaro, M. (1988). Using qualitative analytical techniques. In N. F. Woods & M. Catanzaro (Eds.), Nursing research: Theory and practice. C.V. Mosby: St Louis, MO.
26.
Zurück zum Zitat Jensen, R. E., Snyder, C. F., Abernethy, A. P., Basch, E., Potosky, A. L., Roberts, A. C., et al. (2014). Review of electronic patient-reported outcomes systems used in cancer clinical care. Journal of Oncology Practice, 10(4), e215–e222.CrossRefPubMedPubMedCentral Jensen, R. E., Snyder, C. F., Abernethy, A. P., Basch, E., Potosky, A. L., Roberts, A. C., et al. (2014). Review of electronic patient-reported outcomes systems used in cancer clinical care. Journal of Oncology Practice, 10(4), e215–e222.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Bush, N., Donaldson, G., Moinpour, C., Haberman, M., Milliken, D., Markle, V., et al. (2005). Development, feasibility and compliance of a web-based system for very frequent QOL and symptom home self-assessment after hematopoietic stem cell transplantation. Quality of Life Research, 14(1), 77–93.CrossRefPubMed Bush, N., Donaldson, G., Moinpour, C., Haberman, M., Milliken, D., Markle, V., et al. (2005). Development, feasibility and compliance of a web-based system for very frequent QOL and symptom home self-assessment after hematopoietic stem cell transplantation. Quality of Life Research, 14(1), 77–93.CrossRefPubMed
28.
Zurück zum Zitat Bliven, B. D., Kaufman, S. E., & Spertus, J. A. (2001). Electronic collection of health-related quality of life data: Validity, time benefits, and patient preference. Quality of Life Research, 10(1), 15–22.CrossRefPubMed Bliven, B. D., Kaufman, S. E., & Spertus, J. A. (2001). Electronic collection of health-related quality of life data: Validity, time benefits, and patient preference. Quality of Life Research, 10(1), 15–22.CrossRefPubMed
29.
Zurück zum Zitat Hjollund, N. H. I., Larsen, L. P., Biering, K., Johnsen, S. P., Riiskjær, E., & Schougaard, L. M. (2014). Use of patient-reported outcome (PRO) measures at group and patient Levels: Experiences from the generic integrated PRO system, WestChronic. Interactive Journal of Medical Research,. doi:10.2196/ijmr.2885.PubMedPubMedCentral Hjollund, N. H. I., Larsen, L. P., Biering, K., Johnsen, S. P., Riiskjær, E., & Schougaard, L. M. (2014). Use of patient-reported outcome (PRO) measures at group and patient Levels: Experiences from the generic integrated PRO system, WestChronic. Interactive Journal of Medical Research,. doi:10.​2196/​ijmr.​2885.PubMedPubMedCentral
30.
Zurück zum Zitat Reeve, B. B., Wyrwich, K. W., Wu, A. W., Velikova, G., Terwee, C. B., Snyder, C. F., et al. (2013). ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Quality of Life Research, 22(8), 1889–1905.CrossRefPubMed Reeve, B. B., Wyrwich, K. W., Wu, A. W., Velikova, G., Terwee, C. B., Snyder, C. F., et al. (2013). ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Quality of Life Research, 22(8), 1889–1905.CrossRefPubMed
Metadaten
Titel
A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms
verfasst von
Nana Brochmann
Ann-Dorthe Zwisler
Mette Kjerholt
Esben Meulengracht Flachs
Hans Carl Hasselbalch
Christen Lykkegaard Andersen
Publikationsdatum
11.09.2015
Verlag
Springer International Publishing
Erschienen in
Quality of Life Research / Ausgabe 4/2016
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-015-1125-1

Weitere Artikel der Ausgabe 4/2016

Quality of Life Research 4/2016 Zur Ausgabe